On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.
Check out the Communication page for the complete details by clicking the link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing...